Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study

被引：0

作者：

Strober, B. ^{[1
]}

Poulin, Y. ^{[2
]}

Kerdel, F. ^{[3
]}

Langley, R. ^{[4
]}

Menter, A. ^{[5
]}

Papp, K. ^{[6
]}

Gu, Y. ^{[7
]}

Okun, M. ^{[7
]}

机构：

[1] NYU, Sch Med, New York, NY USA

[2] Ctr Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[3] Florida Acad Dermatol Ctr, Miami, FL USA

[4] Dalhousie Univ, Halifax, NS, Canada

[5] Baylor Psoriasis Res Inst, Dallas, TX USA

[6] Clin Res, Waterloo, ON, Canada

[7] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2010年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P021

引用

页码：9 / 9

页数：1

共 50 条

[21] Safety and efficacy of leflunomide plus etanercept combination therapy in patients with rheumatoid arthritis:: Results from an open-label pilot study
Grünke, M
Kalden, JR
Manger, B
Antoni, CE
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 421 - 421
[22] Therapeutic efficacy and safety of propylthiouracil in psoriasis: An open-label study
Gnanaraj, Pushpa
Malligarjunan, Hemamalini
Dayalan, Haripriya
Karthikeyan, Subashini
Narasimhan, Murali
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2011, 77 (06): : 673 - 676
[23] Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
Warren, Richard B.
Pavlovsky, Lev
Costanzo, Antonio
Bukhalo, Michael
Korman, Neil J.
Huang, Yu-Huei
Kokolakis, Georgios
Pinter, Andreas
Ibrahim, Nadia
Zheng, Yanbing
Drogaris, Leonidas
Stakias, Vassilis
Soliman, Ahmed M.
Rubant, Simone
Thaci, Diamant
DERMATOLOGY AND THERAPY, 2024, 14 (12) : 3273 - 3290
[24] Etanercept in the treatment of psoriasis vulgaris: Results from an open-label 6-month study
Stratigos, A. J.
Avgerinou, G.
Dessinioti, C.
Antoniou, C.
Stavropoulos, P. G.
Katsambas, A. D.
EADV: PROCEEDINGS OF THE 15TH CONGRESS OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, : 721 - +
[25] ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
Cohen, S.
Pablos, J. L.
Wang, H.
Mueller, G. A.
Kivitz, A.
Matsumoto, A.
Krishnan, E.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 834 - 835
[26] Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis
Papp, Kim
Leonardi, Craig
Gordon, Kenneth
Frevert, Lisa
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB193 - AB193
[27] Adalimumab is effective for psoriasis patients who are primary nonresponders to etanercept: Subanalysis of an open-label clinical trial
Strober, Bruce
Weisman, Jamie
Okun, Martin
Gu, Yihua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB8 - AB8
[28] Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study
Papp, K.
Ho, V.
Teixeira, H. D.
Guerette, B.
Chen, K.
Lynde, C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (08) : 1007 - 1013
[29] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
Paller, Amy
Becker, Emily
de Lucas, Raul
Paris, Maria
Zhang, Wendy
Zhang, Zuoshun
Barcellona, Claire
Maes, Peter
Fiorillo, Loretta
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB120 - AB120
[30] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study
Paller, A.
Becker, E.
de Lucas, R.
Paris, M.
Zhang, W.
Zhang, Z.
Barcellona, C.
Maes, P.
Fiorillo, L.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 174 - 175

← 1 2 3 4 5 →